S&P 500   4,590.84 (+1.28%)
DOW   35,417.96 (+1.11%)
QQQ   373.55 (+1.93%)
AAPL   169.28 (+1.83%)
MSFT   310.79 (+2.46%)
FB   326.75 (+2.24%)
GOOGL   2,747.52 (+1.67%)
AMZN   3,149.85 (+0.76%)
TSLA   1,037.82 (+4.24%)
NVDA   255.17 (+1.80%)
BABA   134.29 (+5.13%)
NIO   30.56 (+6.74%)
AMD   127.28 (-0.77%)
CGC   8.08 (+5.76%)
MU   89.76 (-0.27%)
GE   101.61 (+0.98%)
T   27.28 (+0.00%)
F   22.72 (+1.20%)
DIS   152.04 (+1.29%)
AMC   19.12 (+4.37%)
PFE   53.46 (-0.15%)
ACB   5.04 (+3.70%)
BA   220.70 (+1.67%)
S&P 500   4,590.84 (+1.28%)
DOW   35,417.96 (+1.11%)
QQQ   373.55 (+1.93%)
AAPL   169.28 (+1.83%)
MSFT   310.79 (+2.46%)
FB   326.75 (+2.24%)
GOOGL   2,747.52 (+1.67%)
AMZN   3,149.85 (+0.76%)
TSLA   1,037.82 (+4.24%)
NVDA   255.17 (+1.80%)
BABA   134.29 (+5.13%)
NIO   30.56 (+6.74%)
AMD   127.28 (-0.77%)
CGC   8.08 (+5.76%)
MU   89.76 (-0.27%)
GE   101.61 (+0.98%)
T   27.28 (+0.00%)
F   22.72 (+1.20%)
DIS   152.04 (+1.29%)
AMC   19.12 (+4.37%)
PFE   53.46 (-0.15%)
ACB   5.04 (+3.70%)
BA   220.70 (+1.67%)
S&P 500   4,590.84 (+1.28%)
DOW   35,417.96 (+1.11%)
QQQ   373.55 (+1.93%)
AAPL   169.28 (+1.83%)
MSFT   310.79 (+2.46%)
FB   326.75 (+2.24%)
GOOGL   2,747.52 (+1.67%)
AMZN   3,149.85 (+0.76%)
TSLA   1,037.82 (+4.24%)
NVDA   255.17 (+1.80%)
BABA   134.29 (+5.13%)
NIO   30.56 (+6.74%)
AMD   127.28 (-0.77%)
CGC   8.08 (+5.76%)
MU   89.76 (-0.27%)
GE   101.61 (+0.98%)
T   27.28 (+0.00%)
F   22.72 (+1.20%)
DIS   152.04 (+1.29%)
AMC   19.12 (+4.37%)
PFE   53.46 (-0.15%)
ACB   5.04 (+3.70%)
BA   220.70 (+1.67%)
S&P 500   4,590.84 (+1.28%)
DOW   35,417.96 (+1.11%)
QQQ   373.55 (+1.93%)
AAPL   169.28 (+1.83%)
MSFT   310.79 (+2.46%)
FB   326.75 (+2.24%)
GOOGL   2,747.52 (+1.67%)
AMZN   3,149.85 (+0.76%)
TSLA   1,037.82 (+4.24%)
NVDA   255.17 (+1.80%)
BABA   134.29 (+5.13%)
NIO   30.56 (+6.74%)
AMD   127.28 (-0.77%)
CGC   8.08 (+5.76%)
MU   89.76 (-0.27%)
GE   101.61 (+0.98%)
T   27.28 (+0.00%)
F   22.72 (+1.20%)
DIS   152.04 (+1.29%)
AMC   19.12 (+4.37%)
PFE   53.46 (-0.15%)
ACB   5.04 (+3.70%)
BA   220.70 (+1.67%)
NASDAQ:BIOC

Biocept Stock Forecast, Price & News

$3.20
+0.06 (+1.91%)
(As of 01/20/2022 10:46 AM ET)
Add
Compare
Today's Range
$3.20
$3.23
50-Day Range
$3.14
$4.22
52-Week Range
$3.10
$8.38
Volume
400 shs
Average Volume
181,085 shs
Market Capitalization
$53.89 million
P/E Ratio
14.55
Dividend Yield
N/A
Beta
0.48
30 days | 90 days | 365 days | Advanced Chart
Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.


Biocept logo

About Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
107
Year Founded
N/A

Sales & Book Value

Annual Sales
$27.46 million
Book Value
$1.77 per share

Profitability

Net Income
$-17.81 million
Pretax Margin
4.71%

Debt

Price-To-Earnings

Miscellaneous

Free Float
16,608,000
Market Cap
$53.89 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/20/2022
Next Earnings (Estimated)
4/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.17 out of 5 stars

Medical Sector

1169th out of 1,415 stocks

Medical Laboratories Industry

26th out of 31 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept
or view top-rated stocks.

How has Biocept's stock been impacted by COVID-19?

Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BIOC shares have decreased by 15.1% and is now trading at $3.20.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Biocept?

Biocept saw a decrease in short interest in December. As of December 15th, there was short interest totaling 372,700 shares, a decrease of 29.1% from the November 30th total of 525,900 shares. Based on an average daily trading volume, of 264,900 shares, the days-to-cover ratio is presently 1.4 days.
View Biocept's Short Interest
.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Biocept
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its earnings results on Monday, November, 15th. The medical research company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.06. The medical research company had revenue of $17.47 million for the quarter, compared to the consensus estimate of $16.87 million. Biocept had a net margin of 4.71% and a trailing twelve-month return on equity of 10.35%. During the same quarter last year, the firm posted ($0.43) earnings per share.
View Biocept's earnings history
.

When did Biocept's stock split? How did Biocept's stock split work?

Shares of Biocept reverse split on the morning of Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Michael W. Nall, President, Chief Executive Officer & Director
  • Timothy C. Kennedy, CFO, Senior VP-Operations & Secretary
  • Lyle J. Arnold, Chief Scientific Officer & Senior Vice President
  • Michael C. Dugan, Chief Medical Officer & Medical Director
  • Michael W. Brown, General Counsel, Compliance & Privacy Officer

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $3.20.

How much money does Biocept make?

Biocept has a market capitalization of $53.89 million and generates $27.46 million in revenue each year. The medical research company earns $-17.81 million in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 107 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

Where are Biocept's headquarters?

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.